Bristol-Myers Squibb Discontinues Development of BMS-986094 for the Treatment of Hepatitis C
Bristol-Myers Squibb Company announced that the Company has discontinued development of BMS-986094 (formerly known as INX-189), a nucleotide polymerase (NS5B) inhibitor that was in Phase II development for the treatment of hepatitis C. This decision was made in the interest of patient safet ... more
